Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918266 · ClinicalTrials.gov registry record · Phase 1
TAK-071 Scopolamine-Induced Cognitive Impairment Study
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02918266 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 18 participants.
The verdict
NCT02918266, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of a single oral dose of TAK-071 on the attenuation of cognitive deficit induced by scopolamine as measured by Groton Maze Learning Test (GMLT) (total number of errors).
Interventions
- DRUG Donepezil
- DRUG Scopolamine
- DRUG TAK-071
- DRUG TAK-071 Placebo
- DRUG Scopolamine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-11-21 |
| Est. Completion | 2017-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02918266
The ClinicalTrials.gov registry entry for NCT02918266 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Donepezil is the first listed.
NCT02918266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02918266 about?
NCT02918266 is a clinical study titled "TAK-071 Scopolamine-Induced Cognitive Impairment Study". The purpose of this study is to assess the effect of a single oral dose of TAK-071 on the attenuation of cognitive deficit induced by scopolamine as measured by Groton Maze Learning Test (GMLT) (total number of errors).
What is the current status of trial NCT02918266?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-11-21. Estimated completion is 2017-08-08.
What interventions are being tested in trial NCT02918266?
The interventions under investigation include: Donepezil (DRUG), Scopolamine (DRUG), TAK-071 (DRUG), TAK-071 Placebo (DRUG), Scopolamine Placebo (DRUG).
Who is sponsoring clinical trial NCT02918266?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.